Physician profile
Peter Ping Lee
NPI 1205828993
$15,232.65
in general payments reported to CMS, 2019-2025
68 companies · $2,149 in 2025
The $2,149 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,620 · 2020: $1,694 · 2021: $2,383 · 2022: $1,994 · 2023: $3,167 · 2024: $2,225 · 2025: $2,149.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,315 · Travel and Lodging: $1,153 · Education: $72.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,314.62 |
| Travel and Lodging | $1,153.29 |
| Education | $72.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Livanova USA, INC. | $1,525.54 | 2023 | Vns Therapy, Vns Therapy Sentiva Model 1000 Generator |
| Lilly USA, LLC | $892.69 | 2019-2025 | Emgality, Mounjaro, Amyvid |
| Abbvie INC. | $838.79 | 2021-2025 | |
| Emd Serono, INC. | $743.63 | 2019-2025 | Mavenclad, Mavenclad |
| Amgen INC. | $729.16 | 2019-2025 | Repatha, Otezla, Otezla |
| Eisai INC. | $512.10 | 2020-2025 | |
| Novo Nordisk INC | $502.26 | 2019-2025 | Rybelsus, Ozempic |
| Greenwich Biosciences, INC. | $455.76 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $447.86 | 2019-2022 | |
| Neurocrine Biosciences, INC. | $410.03 | 2022-2025 | Ingrezza |
| Pfizer INC. | $398.18 | 2019-2025 | |
| Biohaven Pharmaceuticals, INC. | $369.67 | 2021 | |
| Scilex Pharmaceuticals INC. | $354.15 | 2019-2025 | Ztlido |
| Lundbeck LLC | $332.53 | 2022-2024 | Vyepti, Rexulti |
| Biogen, INC. | $324.58 | 2019-2025 | Vumerity, Tysabri, Avonex |
Show all 68 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.